Professor David F. Penson

David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University Medical Center.  He obtained his MD from Boston University and completed his urology residency at UCLA Medical Center in Los Angeles. He then was awarded a Robert Wood Johnson Clinical Scholar fellowship at Yale University and also obtained an MPH at Yale. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center.  His specific research interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients’ quality of life. He has received federal grant funding from the National Cancer Institute, the US Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention and the Patient-Centered Outcomes Research Institute.  His work has been published in various high-profile journals, including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine.  He previously chaired the National Institutes of Health’s Health Services Outcomes and Delivery (HSOD) study section, which reviews almost all health services research grant submitted to the NIH.  He also maintains a strong interest in health policy and quality improvement. He currently serves as the Secretary of the American Urological Association.

Associate Professor Anna Lantz

Anna Lantz is an Associate Professor of Urology at Karolinska Institutet and a Consultant Urologist at Karolinska University Hospital Solna. 

Her work focuses on the detection and treatment of prostate cancer, integrating clinical practice with independent research at Karolinska Institutet. Between 2019 and 2020, Dr Lantz completed international postdoctoral studies at the Icahn School of Medicine at Mount Sinai Hospital in New York. She is medically responsible for Organized Prostate Cancer Testing (OPT) in the Stockholm Gotland region and leads the Prostate Cancer IRE Study (PRIS), a randomized controlled trial comparing focal to radical treatment in localized prostate cancer. Her broader research interests include improving diagnostics and follow-up for men with low-risk prostate cancer, particularly through the STHLM3AS and international STHLM3AS-NorDCaP studies, as well as participation as Principal Investigator in the EMBARK trial.

Professor Henk van der Poel

Professor Henk van der Poel is head of the department of urology at the Netherlands Cancer Center in Amsterdam (NL) and endowed-professor the Free-University, Amsterdam (NL). Main focuses of research are the role of image-guided  surgery in the management of urological oncological diseases and the perioperative network cancer-care for prostate cancer. He is editor-in-chief of the Dutch Journal of Urology.

Professor Robert Reiter

Dr. Reiter is the Bing Professor of Urologic Oncology and Chief of the Division of Urologic Oncology. He attended Stanford Medical School, completed his urologic training at Stanford and Baylor College of Medicine, and completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute.

Dr. Reiter is an internationally recognized expert in all areas of prostate cancer management and research. He was among the first to integrate functional MRI imaging and PSMA PET imaging into the diagnosis, surgical management, and care of men with prostate cancer. He was also an early innovator in the field of robotic surgery, and has completed more than 2,500 robotic prostatectomies. In addition to surgical management of prostate cancer, Dr. Reiter has expertise in MRI-guided biopsies to diagnose prostate cancer, focal therapy to treat select individuals, as well as all forms of medical therapy. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans in collaboration with UCLA leaders in the areas of radiation, medical and nuclear prostate oncology.

In addition to his broad clinical interests in prostate cancer, Dr. Reiter is a leading researcher in prostate cancer and has led UCLA’s 12 million SPORE grant, which supports work to translate laboratory discoveries into clinical advances, for more than 15 years. Drugs such as enzalutamide and apalutamide, and imaging tools such as PSMA PET, are among the many advances that have emanated from this program. His own laboratory discovered the prostate stem cell antigen and developed antibodies to target this protein, which has led to novel imaging and therapeutic approaches for prostate cancer currently in clinical trials. Dr. Reiter has authored more than 250 papers and lectures nationally and internationally on all aspects of clinical care of men with prostate cancer

Associate Professor Giorgio Gandaglia

Giorgio Gandaglia is Associate Professor of Urology at Vita-Salute San Raffaele University in Milan and Deputy Head of the Department of Urology at IRCCS San Raffaele Hospital, directed by Professor Francesco Montorsi. He graduated with honors in Medicine and Surgery and completed his residency in Urology with honors at Vita-Salute San Raffaele University. He subsequently completed a Clinical Research Fellowship at the Cancer Prognostics and Health Outcomes Unit, University of Montreal (Canada) in 2013, and a Fellowship in Robot-Assisted Surgery at the OLV Robotic Surgery Institute in Aalst (Belgium) in 2015.

Professor Gandaglia is actively involved in major international scientific societies. He is a member of the EAU Prostate Cancer Guidelines Panel, a Board Member of the EAU Section of Uro-Oncology (ESOU), and an Assistant Editor of European Urology. From 2019 to 2024, he chaired the Prostate Cancer Group of the EAU Young Academic Urologists (YAU) and is an Associate Member of the EAU Robotic Urology Section (ERUS).

His research activity includes approximately 650 PubMed-indexed publications with an H-index of 68 (Scopus). He is Principal Investigator of several competitively funded research projects, including grants from the Italian Ministry of Health and the Italian Association for Cancer Research (AIRC), focusing on the integration of molecular biology and advanced imaging in prostate cancer.

Professor Gandaglia has received several prestigious awards, including the European Urology Reviewer of the Year Award (2015), the ESUI Vision Award (2019), the EAU Best Paper in Urological Literature Award for Clinical Research (2019), the SIU Matula Italian Award (2023), and the EAU Crystal Matula Award (2024), recognizing the most promising European urologist under the age of 40.

Debbie Victor

Debbie has been a Urology nurse since 1991 and an uro-oncology CNS since 2004. She is the BAUN Education Lead and was awarded with both the BJN Urology Nurse of the Year 2019 and TUF Nurse of the Year 2022. Her projects include remote self-monitoring of stable prostate cancer men, nurse led TRUS and then LATP being part of working party with NHS England to write LATP guidelines in 2025. As a Prostate Cancer UK Clinical Champion Debbie created a programme of education for practice nurses making ‘every contact count’ when administering LHRHa. Debbie’s other initiatives include nurse led ARPI clinic and Healthy on Hormones workshop for men starting ADT. She works closely with prostate cancer charities, reviewing literature and was a PCUK Clinical Advisor.

Associate Professor James Porter

A/Professor James Porter, is Director of Robotic Surgery for Providence St. Joseph Health and Swedish Medical Center. He is the most experienced robotic surgeon in the Pacific Northwest and has performed over 5000 robotic procedures. He is Director of the Robotic and Laparoscopic Fellowship in Urology at Swedish Medical Center over the last 22 years. He is recognized as a national and international leader in robotic surgery and is active in teaching robotic surgical techniques to surgeons around the globe. He pioneered the retroperitoneal approach for robotic renal surgery as well as retroperitoneal lymph node dissection for the treatment of testicular cancer.

Supported by:

Professor Jonathan A. Coleman

Jonathan A. Coleman, MD, is a Cancer Surgeon at Memorial Sloan Kettering Cancer Center in New York where he a Professor of Urology in the Department of Surgery, Vice-Chair of Surgical Innovation and Technology, and the David H. Koch Chair in Surgery. Dr Coleman specializes in minimally invasive and image guided therapies for malignancies of the kidney, upper urinary tract and prostate. He received his Doctor of Medicine degree from Cornell University Medical College in 1996 followed by residency in General Surgery and Urology (1996-2002) at The New York Hospital in New York City with E. Darracott Vaughan, MD. From 2002 – 2004 Dr. Coleman completed his Fellowship training in Urologic Oncology at the National Institutes of Health / National Cancer Institute (NCI) in Bethesda, Maryland including research on urothelial cancer and hereditary forms of kidney cancer with Marston Linehan, MD. 

He served on staff at the NCI as Attending Surgeon and Senior Research Scientist, collaborating with Don Bottaro, PhD on research of c-MET expression and targeted inhibition in urothelial cancer. In 2006 he joined the faculty at Memorial Sloan Kettering under Peter Scardino, MD and James Eastham, MD . Dr Coleman is a physician-scientist focused on translational research, cancer genomics, and patient-derived organoid models in the study of upper tract urothelial cancer. 

He is the loving husband of Dr Hanna Rodriguez Coleman, a retinal surgeon who practices at Columbia-Presbyterian Hospital in New York City, and father to his 3 sons, Jarrett, Wyatt, and Jake.

Professor Oliver Sartor

Dr. Oliver Sartor is Director of the newly established Transformational Prostate Cancer Research Center in Louisiana, where he will be responsible for both providing direct patient care and continuing his groundbreaking research, with a primary focus on improving both the longevity and quality of life for men diagnosed with prostate cancer. He previously served as Professor of medical oncology and director of radiopharmaceutical trials at Mayo Clinic in Rochester, MN, and prior to that as Laborde Professor of Medicine and Urology and Medical Director of the Tulane Cancer Center in New Orleans, LA. An internationally recognized prostate cancer specialist, he earned his MD with honors at Tulane University School of Medicine and completed his training at the University of Pennsylvania, Tulane, and the National Cancer Institute. He subsequently focused his clinical practice and research on prostate malignancies since 1990.

Dr Sartor has led or co-led numerous clinical trials, including multiple pivotal phase III studies that supported US FDA approvals for advanced prostate cancer therapies. His scholarship encompasses more than 500 publications including multiple publications in the New England Journal of Medicine and Lancet, with significant contributions to the development of cabazitaxel, olaparib, radium-223 and lutetium-177 PSMA-targeted treatments. In recognition of his leadership in practice-changing radiopharmaceutical trials, he was named an honorary member of the American Society of Radiation Oncology (ASTRO) in 2023. He has lectured widely on prostate cancer and has been invited to lecture in 34 countries (at last count).

Supported by:

Professor Sean Collins

Dr. Sean P. Collins is a highly accomplished radiation oncologist who served as the Director of the CyberKnife Prostate Program at Georgetown University Hospital in Washington, D.C. For twenty years. He recently moved to the Department of Radiation Oncology at the University of South Florida where he serves as Professor and Vice Chair of Faculty Affairs.

 Dr. Collins has dedicated over two decades to advancing the treatment of prostate cancer. Specifically, he has treated over 2500 men with prostate cancer utilizing the CyberKnife. He has been at the forefront of innovative radiation therapies. In addition to his clinical expertise, Dr. Collins is a prolific researcher and educator, contributing to national and international efforts to improve cancer treatment outcomes. He has published over 300 peer reviewed articles and abstracts many of with evaluated patient reported outcomes (PRO) following prostate cancer treatment. He has obtained grant funding from the National Cancer Institute focusing on determinants of racial disparity in prostate cancer. Has served as an active member of the Alliance in Oncology Radiation Oncology and GU Committees since 2010. He currently serves on the steering committee for two trials assessing the potential benefits of rectal spacers with prostate radiotherapy. Most recently he was selected as incoming Chair of the Programmatic Panel for the Department of Defense (DOD) Prostate Cancer Research Program. Recognized for his leadership in prostate cancer care, Dr. Collins continues to push the boundaries of cancer treatment, while mentoring the next generation of radiation oncologists.

Associate Professor Kara Watts

Kara Watts is Associate Professor and Vice Chair of Urology at Montefiore Medical Center/Albert Einstein College of Medicine, United States where she serves as the Director of Quality and Urologic Cancer Services. Associate Professor Watts holds a Green Belt certification in Lean Six Sigma methodology and completed fellowship training in focal therapy for prostate cancer in the UK. Her research and clinical focus include prostate cancer detection and ablation, specifically image-guided focal ablation. She has also lead discussions on the outcomes of emerging modalities and salvage focal ablation for radiorecurrent localized prostate cancer. She has authored numerous peer-reviewed studies investigating the long-term efficacy of ablative technologies—such as High-Intensity Focused Ultrasound (HIFU) and cryotherapy while simultaneously publishing frameworks for system-wide quality improvement. Her recent work delves into the "value-based care" model seeking to reduce treatment-related morbidity and healthcare disparities through standardized, data-driven diagnostic protocols.

Associate Professor Watts was awarded the 2026 AUA Gold Cystoscope Award acknowledging pioneering research in prostate cancer diagnostics, focal therapy and systematic quality improvement methodologies.